Phase 3 Trial to Evaluate Efficacy & Safety of Aficamten (CK-3773274) in oHCM (SEQUOIA-HCM)

• Research type

  Research Study

• Full title

  A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

• IRAS ID

  1005127

• Contact name

  Lynsey Kennedy

• Contact email

  Irasuk@iconplc.com

• Sponsor organisation

  Cytokinetics, Inc.

• Eudract number

  2021-003536-92

• Clinicaltrials.gov Identifier

  NCT05186818

• Research summary

  The purpose of this study is to determine the effects of CK-3773274 on exercise capacity and general health status of participants with oHCM. The safety and tolerability of CK-3773274 will also be studied.

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  22/EM/0083

• Date of REC Opinion

  25 May 2022

• REC opinion

  Further Information Favourable Opinion